Laverock Therapeutics
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $25.9Mattributed |
|---|---|
| Latest round | seed, $25.2M, 2025-06-01attributed |
| Founded | 2021 |
| Headquarters | London, United Kingdom |
| Industry | bio |
| Stage | seed |
| Website | laverocktx.com |
Laverock Therapeutics develops programmable advanced therapies using RNA-based gene-control and cell-engineering platforms. It serves patients with unmet needs in oncology and beyond, plus partners across applications. Its disease-responsive systems fine-tune gene expression dynamically rather than using simple on/off switches.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | seed | $25.2M | undisclosed |
Detected tech stack
Cloudflare, LottieFiles 5.12.2, Google Font API, Google Hosted Libraries, Google Tag Manager, jquery 3.5.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $25.2M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $25.9M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | laverocktx.com, read 2026-05-08 |
| Description | self-reported | laverocktx.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.